Literature DB >> 15764083

AMD and micronutrient antioxidants.

Ruth Hogg1, Usha Chakravarthy.   

Abstract

Age-related maculopathy (ARM) is a common clinical entity. The late-stage manifestations of ARM, which are known as age-related macular degeneration (AMD), have devastating consequences for vision. Various risk factors have been identified in the development of the condition, which are consistent with the premise that oxidative stress plays an important role in its pathogenesis. Thus, the possibility that antioxidant balance can be manipulated through diet or supplementation has created much interest. Associations between diet and nutrition and the clinical features of ARM have been described. Scrutiny of the literature shows consistency in the report of notable reductions in serum micronutrients in wet AMD, however, the evidence for causation is still circumstantial. In this comprehensive review of the clinical literature, we have assessed the evidence for a link between diet and nutrition as risk factors for the development of ARM and AMD. All published case control, population-based, and interventional studies on ARM were examined. Although initial support appeared to be moderate and somewhat contradictory, the evidence that lifetime oxidative stress plays an important role in the development of ARM is now compelling. The positive outcomes in the Age-Related Eye Diseases Study, a major controlled clinical trial, have given hope that modulation of the antioxidant balance through supplementation can help prevent progression of ARM to AMD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15764083     DOI: 10.1080/02713680490517890

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  20 in total

Review 1.  Lifestyle exposures and eye diseases in adults.

Authors:  Barbara E K Klein; Ronald Klein
Journal:  Am J Ophthalmol       Date:  2007-10-18       Impact factor: 5.258

Review 2.  Age related macular degeneration.

Authors:  Jennifer J Arnold; Wilson Heriot
Journal:  BMJ Clin Evid       Date:  2007-04-01

Review 3.  Obesity and eye diseases.

Authors:  Ning Cheung; Tien Y Wong
Journal:  Surv Ophthalmol       Date:  2007 Mar-Apr       Impact factor: 6.048

4.  Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians.

Authors:  William G Christen; Joann E Manson; Robert J Glynn; J Michael Gaziano; Emily Y Chew; Julie E Buring; Charles H Hennekens
Journal:  Arch Ophthalmol       Date:  2007-03

5.  Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells.

Authors:  Wen-Chuan Wu; Dan-Ning Hu; Hua-Xin Gao; Min Chen; Dawei Wang; Richard Rosen; Steven A McCormick
Journal:  Mol Vis       Date:  2010-09-12       Impact factor: 2.367

6.  The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration.

Authors:  Kyung Hwa Kang; Greg Lemke; Jin Woo Kim
Journal:  Trends Mol Med       Date:  2009-04-18       Impact factor: 11.951

Review 7.  [Lutein and antioxidants in the prevention of age-related macular degeneration].

Authors:  M Rehak; E Fric; P Wiedemann
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

8.  Selective degeneration of central photoreceptors after hyperbaric oxygen in normal and metallothionein-knockout mice.

Authors:  Michele Nachman-Clewner; Frank J Giblin; C Kathleen Dorey; Robert H I Blanks; Loan Dang; Christopher J Dougherty; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07       Impact factor: 4.799

9.  Zeaxanthin is bioavailable from genetically modified zeaxanthin-rich potatoes.

Authors:  Achim Bub; Jutta Möseneder; Gerhard Wenzel; Gerhard Rechkemmer; Karlis Briviba
Journal:  Eur J Nutr       Date:  2008-03-04       Impact factor: 5.614

10.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.